Disc Medicine initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Jeffrey Hung initiated coverage of Disc Medicine with an Overweight rating and $37 price target. Initial data for bitopertin and DISC-0974 have been "encouraging," and multiple data readouts are expected this year, the analyst tells investors in a research note. The firm says Disc is developing a portfolio of drug candidates to modulate heme synthesis and iron.